SG11202102684VA - Treatment for non-alcoholic fatty liver disease - Google Patents
Treatment for non-alcoholic fatty liver diseaseInfo
- Publication number
- SG11202102684VA SG11202102684VA SG11202102684VA SG11202102684VA SG11202102684VA SG 11202102684V A SG11202102684V A SG 11202102684VA SG 11202102684V A SG11202102684V A SG 11202102684VA SG 11202102684V A SG11202102684V A SG 11202102684VA SG 11202102684V A SG11202102684V A SG 11202102684VA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- liver disease
- fatty liver
- alcoholic fatty
- alcoholic
- Prior art date
Links
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732644P | 2018-09-18 | 2018-09-18 | |
| PCT/US2019/051790 WO2020061232A1 (en) | 2018-09-18 | 2019-09-18 | Treatment for non-alcoholic fatty liver disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102684VA true SG11202102684VA (en) | 2021-04-29 |
Family
ID=69888816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102684VA SG11202102684VA (en) | 2018-09-18 | 2019-09-18 | Treatment for non-alcoholic fatty liver disease |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12318381B2 (enExample) |
| EP (1) | EP3852753A4 (enExample) |
| JP (2) | JP7557788B2 (enExample) |
| KR (1) | KR102890555B1 (enExample) |
| CN (1) | CN112955143B (enExample) |
| AU (1) | AU2019345297B2 (enExample) |
| BR (1) | BR112021005086A2 (enExample) |
| CA (1) | CA3113016A1 (enExample) |
| MX (1) | MX2021003156A (enExample) |
| SG (1) | SG11202102684VA (enExample) |
| TW (1) | TWI825177B (enExample) |
| WO (1) | WO2020061232A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017324510B2 (en) | 2016-09-07 | 2023-08-31 | Temple University - Of The Commonwealth System Of Higher Education | Compositions and methods for treatment of insulin resistance |
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| TW202206062A (zh) | 2020-04-24 | 2022-02-16 | 美國坦普大學 高等教育聯邦系統 | 治療非酒精性脂肪肝炎的方法 |
| WO2022040324A1 (en) * | 2020-08-18 | 2022-02-24 | Metrea Biosciences, Inc. | COMPOUNDS AND METHODS OF MODULATING 17β-ΗYDROXYSTEROID DEHYDROGENASE TYPE 13 |
| WO2023174543A1 (en) * | 2022-03-17 | 2023-09-21 | Siemens Industry Software GmbH | Managing artifact information relating to a physical system, especially improving traceability of re-baselined engineering-related information, method and system |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008100977A2 (en) | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| CA2736177A1 (en) * | 2007-09-06 | 2009-03-12 | Boston Biomedical, Inc. | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| US8889730B2 (en) * | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| US20160031888A1 (en) * | 2013-03-13 | 2016-02-04 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| WO2014202528A1 (en) | 2013-06-20 | 2014-12-24 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
| EP2886541A1 (en) | 2013-12-19 | 2015-06-24 | Sanofi | Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases |
| AU2015209095A1 (en) * | 2014-01-27 | 2016-07-07 | Boston Biomedical, Inc. | Novel methods for treating cancer |
| WO2017026119A1 (ja) * | 2015-08-10 | 2017-02-16 | 大日本住友製薬株式会社 | ５－（チアゾール－４－イル）インドリン－２－オン誘導体の精製方法 |
| US20170105996A1 (en) | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries, Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
| HK1257929A1 (zh) | 2015-11-06 | 2019-11-01 | Gemphire Therapeutics Inc. | 治疗混合性血脂异常 |
| WO2018005444A2 (en) * | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| JP7589949B2 (ja) * | 2018-09-18 | 2024-11-26 | １グローブ バイオメディカル カンパニー， リミテッド | 肥満に対する処置 |
-
2019
- 2019-09-18 WO PCT/US2019/051790 patent/WO2020061232A1/en not_active Ceased
- 2019-09-18 KR KR1020217011261A patent/KR102890555B1/ko active Active
- 2019-09-18 TW TW108133698A patent/TWI825177B/zh active
- 2019-09-18 AU AU2019345297A patent/AU2019345297B2/en active Active
- 2019-09-18 US US17/276,482 patent/US12318381B2/en active Active
- 2019-09-18 BR BR112021005086-8A patent/BR112021005086A2/pt unknown
- 2019-09-18 SG SG11202102684VA patent/SG11202102684VA/en unknown
- 2019-09-18 CN CN201980061364.1A patent/CN112955143B/zh active Active
- 2019-09-18 JP JP2021539501A patent/JP7557788B2/ja active Active
- 2019-09-18 MX MX2021003156A patent/MX2021003156A/es unknown
- 2019-09-18 EP EP19861804.3A patent/EP3852753A4/en active Pending
- 2019-09-18 CA CA3113016A patent/CA3113016A1/en active Pending
-
2024
- 2024-09-04 JP JP2024152701A patent/JP2024163257A/ja active Pending
-
2025
- 2025-05-19 US US19/212,109 patent/US20250275960A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022501436A (ja) | 2022-01-06 |
| MX2021003156A (es) | 2021-05-14 |
| AU2019345297B2 (en) | 2024-12-05 |
| CN112955143B (zh) | 2023-10-13 |
| EP3852753A4 (en) | 2022-06-08 |
| BR112021005086A2 (pt) | 2021-06-08 |
| CN112955143A (zh) | 2021-06-11 |
| US20250275960A1 (en) | 2025-09-04 |
| JP2024163257A (ja) | 2024-11-21 |
| JP7557788B2 (ja) | 2024-09-30 |
| EP3852753A1 (en) | 2021-07-28 |
| TW202034910A (zh) | 2020-10-01 |
| AU2019345297A1 (en) | 2021-04-29 |
| KR20210079290A (ko) | 2021-06-29 |
| KR102890555B1 (ko) | 2025-11-24 |
| NZ774401A (en) | 2025-02-28 |
| CA3113016A1 (en) | 2020-03-26 |
| WO2020061232A1 (en) | 2020-03-26 |
| US20220040172A1 (en) | 2022-02-10 |
| TWI825177B (zh) | 2023-12-11 |
| US12318381B2 (en) | 2025-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201705361PA (en) | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease | |
| SG11202102684VA (en) | Treatment for non-alcoholic fatty liver disease | |
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| IL259133A (en) | Jamkaban combinations for the treatment of cardiovascular disease | |
| EP3448874A4 (en) | COMPOSITIONS FOR TREATING A DISEASE | |
| IL254282A0 (en) | Methods for treating non-alcoholic fatty liver disease and/or lipid metabolism disorder | |
| IL275002A (en) | Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease | |
| IL275496A (en) | Glycolate oxidase inhibitors to treat the disease | |
| SI4122464T1 (sl) | Terapevtske kombinacije za zdravljenje bolezni jeter | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| IL253945B (en) | kdm1a inhibitors to treat the disease | |
| IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
| GB201411467D0 (en) | 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld) | |
| HRP20260171T1 (hr) | Peptidi za liječenje i prevenciju bolesti nealkoholne masne jetre | |
| IL281878A (en) | Cold solutions for reducing fat | |
| EP3132795A4 (en) | Composition for preventing or treating fatty liver diseases | |
| IL263161B (en) | New compounds for the treatment of parasitic diseases | |
| EP3256860A4 (en) | Methods and compositions for identifying non-alcoholic fatty liver disease | |
| EP3362053A4 (en) | TREATMENT OF NON-ALCOHOLIC FATTYLENE OR NON-ALCOHOLIC STEATOHEPATITIS WITH 6-MERCAPTOPURIN WITH DELAYED RELEASE | |
| PL3484475T3 (pl) | 1-Metylonikotynamid do leczenia choroby układu krążenia | |
| PL3233074T3 (pl) | Leczenie niealkoholowych stłuszczeniowych chorób wątroby | |
| IL274747A (en) | FXR agonists for the treatment of liver diseases | |
| HK40047110A (en) | Treatment for non-alcoholic fatty liver disease | |
| EP3675888A4 (en) | S. SPINOSUM EXTRACT FOR FAT LIVER TREATMENT | |
| GB201622116D0 (en) | Treatment of liver disease |